Evidence map›Paper›PMID 36645265›Full record

ArticleThe American journal on addictions2023

Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial.

Noel Vest, Kevin Wenzel, Tse-Hwei Choo, Martina Pavlicova, John Rotrosen, Edward Nunes, Joshua D Lee, Marc Fishman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal on addictions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Noel VestDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0001-8014-9726
Kevin WenzelDepartment of Research, Maryland Treatment Centers/Mountain Manor Treatment Center, Baltimore, Maryland, USA.
Tse-Hwei ChooDepartment of Psychiatry, Columbia University, New York, New York, USA.
Martina PavlicovaDepartment of Psychiatry, Columbia University, New York, New York, USA.
John RotrosenDepartment of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
Edward NunesDepartment of Psychiatry, Columbia University, New York, New York, USA.ORCID 0000-0002-2055-3425
Joshua D LeeDepartment of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
Marc FishmanDepartment of Research, Maryland Treatment Centers/Mountain Manor Treatment Center, Baltimore, Maryland, USA.
Columbia University · USNew York University · USJohns Hopkins University · USStanford University · US

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
Clinical Trials Network: Southwest NodeU10DA015833 · NIDA · UNIVERSITY OF NEW MEXICO · PI MCCRADY, BARBARA S · 2002 to 2014
$19.9M
Interdisciplinary Research Training in Pain and Substance Use DisordersT32DA035165 · NIDA · STANFORD UNIVERSITY · PI SEAN C MACKEY · 2013 to 2026
$7.2M
Drug Abuse Treatment Development and Research MentoringK24DA022412 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NUNES, EDWARD V. · 2007 to 2016
$1.7M
NIDA NIH HHS HHSN271201200017CNIDA NIH HHS HHSN271201500065CNIDA NIH HHS K01 DA053391NIDA NIH HHS K01DA053391NIDA NIH HHS K24 DA022412NIDA NIH HHS L30 DA056944NIDA NIH HHS T32 DA035165NIDA NIH HHS T32DA035165NIDA NIH HHS U10 DA013034NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA013046NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013720NIDA NIH HHS U10 DA013732NIDA NIH HHS U10 DA015831NIDA NIH HHS U10 DA015833NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1DA013035
6 · The paper itself

Abstract

BACKGROUND AND

objectivesTo inform clinical practice, we identified subgroups of adults based on levels of depression symptomatology over time during opioid use disorder (OUD) treatment.

methodsParticipants were 474 adults in a 24-week treatment trial for OUD. Depression symptoms were measured using the 17-item Hamilton Depression Rating Scale (HAM-D) at nine-time points. This was a secondary analysis of the Clinical Trials Network Extended-Release Naltrexone versus Buprenorphine for Opioid Treatment (XBOT) trial using a growth mixture model.

resultsThree distinct depression trajectories were identified: Class 1 High Recurring-10% with high HAM-D with initial partial reductions (of HAM-D across time), Class 2 Persistently High-5% with persistently high HAM-D, and Class 3 Low Declining-85% of the participants, with low HAM-D with early sustained reductions. The majority (low declining) had levels of depression that improved in the first 4 weeks and then stabilized across the treatment period. In contrast, 15% (high recurring and persistently high) had high initial levels that were more variable across time. The persistently high class had higher rates of opioid relapse. DISCUSSION AND

conclusionsIn this OUD sample, most depressive symptomatology was mild and improved after medication treatment for opioid use disorder (MOUD). Smaller subgroups had higher depressive symptoms that persisted or recurred after the initiation of MOUD. Depressive symptoms should be followed in patients initiating treatment for OUD, and when persistent, should prompt further evaluation and consideration of antidepressant treatment. SCIENTIFIC SIGNIFICANCE: This study is the first to identify three distinct depression trajectories among a large clinical sample of individuals in MOUD treatment.

Indexed as

BuprenorphineOpioid-Related DisordersAdultAnalgesics, OpioidDepressionHumansNaltrexoneAnalgesics, OpioidBuprenorphineNaltrexone

Identifiers

PMID36645265
PMCPMC10332426
OpenAlexW4316673640

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.